FR20C1036I1 - PERIVASCULAR MESENCHYMAL PRECURSOR CELLS - Google Patents

PERIVASCULAR MESENCHYMAL PRECURSOR CELLS

Info

Publication number
FR20C1036I1
FR20C1036I1 FR20C1036C FR20C1036I1 FR 20C1036 I1 FR20C1036 I1 FR 20C1036I1 FR 20C1036 C FR20C1036 C FR 20C1036C FR 20C1036 I1 FR20C1036 I1 FR 20C1036I1
Authority
FR
France
Prior art keywords
precursor cells
mesenchymal precursor
perivascular mesenchymal
perivascular
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mesoblast Inc
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31500707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR20C1036(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of FR20C1036I1 publication Critical patent/FR20C1036I1/en
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Application granted granted Critical
Publication of FR20C1036I2 publication Critical patent/FR20C1036I2/en
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0668—Mesenchymal stem cells from other natural sources
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0691—Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1392—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from mesenchymal stem cells from other natural sources

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR20C1036C 2003-03-28 2020-08-06 PERIVASCULAR MESENCHYMAL PRECURSOR CELLS Active FR20C1036I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2003901668A AU2003901668A0 (en) 2003-03-28 2003-03-28 Non-haemopoietic precursor cells
EP04723935A EP1613741A4 (en) 2003-03-28 2004-03-29 Perivascular mesenchymal precursor cells
PCT/AU2004/000416 WO2004085630A1 (en) 2003-03-28 2004-03-29 Perivascular mesenchymal precursor cells

Publications (2)

Publication Number Publication Date
FR20C1036I1 true FR20C1036I1 (en) 2020-02-10
FR20C1036I2 FR20C1036I2 (en) 2022-11-18

Family

ID=31500707

Family Applications (1)

Application Number Title Priority Date Filing Date
FR20C1036C Active FR20C1036I2 (en) 2003-03-28 2020-08-06 PERIVASCULAR MESENCHYMAL PRECURSOR CELLS

Country Status (14)

Country Link
US (6) US7947266B2 (en)
EP (4) EP2380971B1 (en)
JP (10) JP2006521096A (en)
CN (4) CN1809632B (en)
AU (7) AU2003901668A0 (en)
CA (4) CA2520273C (en)
DK (1) DK1613335T3 (en)
ES (3) ES2784378T3 (en)
FR (1) FR20C1036I2 (en)
NL (1) NL301059I2 (en)
PL (1) PL1613335T3 (en)
PT (1) PT1613335E (en)
SI (1) SI1613335T1 (en)
WO (2) WO2004084921A1 (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US7670628B2 (en) * 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
AUPQ147799A0 (en) * 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
US8062675B2 (en) 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
US20050158289A1 (en) * 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
BRPI0407221A (en) * 2003-02-11 2006-01-31 John E Davies Wharton Jelly Extract, Method for Obtaining a Human Parent Cell, Methods for Producing a Cell Population, Cell Populations, and Method for Producing Bone Tissue
KR20130100225A (en) 2004-09-24 2013-09-09 안지오블라스트 시스템스 인코퍼레이티드 Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc)
EP1807510A4 (en) 2004-09-24 2008-01-23 Angioblast Systems Inc Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof
US8287853B2 (en) 2005-02-11 2012-10-16 Agency For Science, Technology And Research Methods of culturing mesenchymal stem cells
EP2048227B1 (en) 2005-02-11 2015-08-19 Agency For Science, Technology And Research Methods for proliferating stem cells
KR101446634B1 (en) 2005-04-12 2014-10-16 메소블라스트, 아이엔씨. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
US20080213235A1 (en) * 2005-07-29 2008-09-04 University Of Virginia Patent Foundation Adipose Tissue Stem Cells, Perivascular Cells and Pericytes
EP1780265A1 (en) * 2005-10-25 2007-05-02 Stiftung CAESAR Differentiation of stem cells into chondrocytes
KR20140146220A (en) * 2005-12-22 2014-12-24 제인 에니스 Viable cells from frozen umbilical cord tissue
AU2007247725B2 (en) * 2006-05-05 2013-02-14 Dolores Baksh Immune privileged and modulatory progenitor cells
CN101516385B (en) * 2006-07-12 2013-07-10 成血管细胞系统公司 Treatment of excessive neovascularization
FR2909559B1 (en) * 2006-12-06 2012-09-07 Inst Vaisseaux Et Du Sang CELLULAR PREPARATIONS FOR USE AS AGENT STIMULATING REVASCULARIZATION
WO2008077094A2 (en) * 2006-12-19 2008-06-26 Children's Medical Center Corporation Methods for promoting neovascularization
US20100158874A1 (en) * 2007-02-26 2010-06-24 Mount Sinai Hospital Compositions and Methods for Treating Peripheral Vascular Diseases
JP6062615B2 (en) 2007-08-06 2017-01-18 メゾブラスト，インコーポレーテッド Methods for generating, repairing and / or maintaining connective tissue in vivo
WO2009129616A1 (en) * 2008-04-21 2009-10-29 Tissue Regeneration Therapeutics, Inc. Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents
CN105030828B (en) * 2008-06-25 2020-10-02 麦瑟布莱斯特公司 Repair and/or reconstruction of intervertebral discs
US20110200612A1 (en) * 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
WO2010011185A1 (en) * 2008-07-21 2010-01-28 Agency For Science, Technology And Research Stem cells obtained through in vitro culture with heparan sulfate
KR20200011604A (en) 2008-08-20 2020-02-03 안트로제네시스 코포레이션 Improved cell composition and methods of making the same
MX2008014536A (en) * 2008-11-13 2009-01-16 Internac Para La Terapia Celul Cellular regenerator compound.
ES2651503T3 (en) 2008-11-20 2018-01-26 Mesoblast, Inc. Method to treat or prevent pancreatic dysfunction
KR101764437B1 (en) * 2009-03-20 2017-08-02 메소블라스트, 아이엔씨. Production of reprogrammed pluripotent cells
WO2011022070A2 (en) * 2009-08-20 2011-02-24 The Regents Of The University Of California Perivascular stem cell composition for bone
JP5810089B2 (en) 2009-10-21 2015-11-11 マイカーティス エヌ．ヴェ．ＭｙＣａｒｔｉｓ ＮＶ MCAM as a biomarker for body fluid homeostasis
US9308277B2 (en) 2010-02-25 2016-04-12 Mesoblast International Sàrl Protease-resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
ES2831259T3 (en) 2010-07-02 2021-06-08 Mesoblast Inc Treatment of graft versus host disease
CN103080301B (en) * 2010-08-19 2016-10-19 加州大学董事会 Comprise blood vessel week stem cell and the compositions of NELL-1 albumen
CN101985052B (en) * 2010-08-31 2013-11-06 中国人民解放军第二军医大学 Skin substitute for automatically capturing endothelial progenitor cells and promoting vascularization and construction method thereof
US20130236429A1 (en) * 2010-09-23 2013-09-12 Children's Medical Center Corporation Engineered vascular adipose tissue
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
CA2836488C (en) * 2011-05-19 2021-10-26 Mesoblast, Inc. Methods for treating obesity and/or metabolic syndrome
SG195127A1 (en) * 2011-06-03 2013-12-30 Mesoblast Inc Methods of treating or preventing neurological diseases
AU2012262679B2 (en) 2011-06-03 2016-05-26 Central Adelaide Local Health Network Incorporated Method of treating the effects of stroke
WO2012170495A1 (en) 2011-06-07 2012-12-13 Provasculon, Inc. Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
AU2012278925B2 (en) 2011-07-04 2016-05-19 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
AU2012279995C1 (en) 2011-07-06 2019-10-24 Cell Therapy Limited Progenitor cells of mesodermal lineage
EP2734618B1 (en) * 2011-07-20 2017-06-14 Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung Pluripotent tendon and ligament perivascular cells
CA2853910A1 (en) * 2011-08-29 2013-03-07 Safeguard Cell Technology Inc. Isolating and therapeutic use of perivascular medicinal cells
JP5831059B2 (en) * 2011-09-07 2015-12-09 ソニー株式会社 Optical measuring apparatus, flow cytometer, and optical measuring method
US9177336B2 (en) * 2011-09-08 2015-11-03 Telefonaktiebolaget L M Ericsson (Publ) Apparatuses and methods for recommending a path through an information space
KR102009056B1 (en) 2011-09-09 2019-08-08 메소블라스트, 아이엔씨. Method for increasing osteoblastic function
CN102539736B (en) * 2011-12-16 2015-04-29 北京汉氏联合生物技术有限公司 CD106-positive cells, and identification and preparation method and application thereof
JP6901823B2 (en) 2012-08-01 2021-07-14 ユナイテッド セラピューティクス コーポレイション Treatment of pulmonary arterial hypertension with mesenchymal stem cells
WO2014022376A2 (en) 2012-08-01 2014-02-06 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells
EP3556850A1 (en) * 2012-12-12 2019-10-23 Mesoblast, Inc. Treatment of diseases of endothelial dysfunction and inflammation
EP2931373B1 (en) 2012-12-12 2019-08-21 Mesoblast, Inc. Methods of treating or preventing respiratory conditions
EP3878452B1 (en) * 2013-01-09 2023-09-20 United Therapeutics Corporation Treatment of vasculopathy with prostacyclin and mesenchymal stem cells
US20150037436A1 (en) 2013-07-30 2015-02-05 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3079711A4 (en) * 2013-12-13 2017-05-17 Mesoblast International Sàrl Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
EP3613841B1 (en) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passive replacement of media
US10400218B2 (en) 2014-04-07 2019-09-03 Mesoblast International Sarl Stem cell composition
WO2015157694A1 (en) 2014-04-11 2015-10-15 The Administrators Of The Tulane Educational Fund Cell-surface marker of early msc aging
AU2015273799B2 (en) 2014-06-10 2020-07-02 Mesoblast International Sarl Treatment of immune disorders
KR102263824B1 (en) * 2014-07-11 2021-06-10 가부시키가이샤 메토세라 Cardiac cell culture material
EP3198006B1 (en) 2014-09-26 2021-03-24 Terumo BCT, Inc. Scheduled feed
BR112017012911B1 (en) 2014-12-23 2021-10-05 Mesoblast International Sàrl METHOD FOR TREATMENT OF HEART FAILURE
AU2015371011B2 (en) 2014-12-23 2021-07-15 Mesoblast International Sàrl Prevention of progressive heart failure
WO2016139340A1 (en) 2015-03-04 2016-09-09 Mesoblast International Sàrl Cell culture method for mesenchymal stem cells
EP4015624A1 (en) 2015-05-05 2022-06-22 Mesoblast International Sàrl Potency assay
US10531957B2 (en) 2015-05-21 2020-01-14 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
CN106119189B (en) * 2016-07-11 2020-04-10 山东亚大药业有限公司 Separation and purification method and kit for fetal nucleated red blood cells
IL266175B2 (en) 2016-10-24 2024-01-01 United Therapeutics Corp Enhancement of msc immunomodulatory properties by treprostinil
WO2018092769A1 (en) 2016-11-15 2018-05-24 株式会社カネカ Cell population containing mesenchymal stem cells derived from fetal appendages, method for producing same, and medicinal composition
ES2885080T3 (en) * 2017-02-24 2021-12-13 Metcela Inc Injectable composition comprising fibroblasts for use in the treatment of heart disease
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
AU2018262788A1 (en) 2017-05-04 2019-11-14 Mesoblast International Sàrl Mesenchymal lineage precursor or stem cells with enhanced immunosuppression
BR112020010079A2 (en) 2017-11-22 2020-11-03 Mesoblast International Sàrl cell compositions and treatment methods i
EP3750987A4 (en) 2017-12-28 2021-11-10 Kaneka Corporation Cell population including adhesive stem cells, production method therefor, and pharmaceutical composition
EP3874026A1 (en) 2018-10-31 2021-09-08 Mesoblast International Sàrl Expansion of hematopoietic stem cells
CN109321522A (en) * 2018-11-20 2019-02-12 潍坊市康华生物技术有限公司 A method of preparing dental pulp stem cell
BR112021013158A2 (en) 2019-01-02 2021-09-14 Mesoblast International Sàrl METHOD TO TREAT LUMBAR PAIN
BR112021012923A2 (en) 2019-01-03 2021-09-14 Mesoblast International Sàrl METHOD TO IMPROVE VISUAL ACUITY
WO2020157660A1 (en) 2019-01-28 2020-08-06 Mesoblast International Sárl Method for treating or preventing gastrointestinal bleeding
US20220226386A1 (en) 2019-05-23 2022-07-21 Mesoblast International Sárl Functional recovery from cerebral infarction
WO2020251020A1 (en) 2019-06-14 2020-12-17 株式会社カネカ Cell population including mesenchymal cells, pharmaceutical composition including same, and method for producing same
CN114423860A (en) 2019-08-05 2022-04-29 迈索布拉斯特国际有限公司 Cellular compositions comprising viral vectors and methods of treatment
AU2021324483A1 (en) 2020-08-10 2023-04-13 Mesoblast International Sàrl Cellular compositions and methods of treatment
WO2023238074A1 (en) 2022-06-08 2023-12-14 Mesoblast International Sarl Mesenchymal progenitor cells for enhancing partial reprogramming of target cells
CN115184246B (en) * 2022-09-14 2023-07-04 天津昂赛细胞基因工程有限公司 Method for evaluating biological efficacy of mesenchymal stem cells by using CD155
WO2024121821A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Conditioned media and use of the same
WO2024121818A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Method of treating heart failure in subjects with persistent inflammation
WO2024121820A1 (en) 2022-12-09 2024-06-13 Mesoblast International Sarl Pre-licensed composition and cell culture methods

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5226914A (en) * 1990-11-16 1993-07-13 Caplan Arnold I Method for treating connective tissue disorders
US5837539A (en) * 1990-11-16 1998-11-17 Osiris Therapeutics, Inc. Monoclonal antibodies for human mesenchymal stem cells
US5197985A (en) * 1990-11-16 1993-03-30 Caplan Arnold I Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
US5811094A (en) * 1990-11-16 1998-09-22 Osiris Therapeutics, Inc. Connective tissue regeneration using human mesenchymal stem cell preparations
US5486359A (en) * 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
IL107642A0 (en) * 1992-11-20 1994-02-27 Amgen Inc Progenitor b cell stimulating factor
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
US5591625A (en) * 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
US5405722A (en) * 1993-12-22 1995-04-11 Rca Thomson Licensing Corp. Method for combined baking-out and sealing of an electrophotographically processed screen assembly for a cathode-ray tube
US5792453A (en) 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
AU1119397A (en) * 1995-11-14 1997-06-05 Regents Of The University Of Minnesota Ex vivo culture of stem cells
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6335195B1 (en) * 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
DE69837491T2 (en) * 1997-07-03 2008-01-17 Osiris Therapeutics, Inc. HUMAN MESENCHYMAL STEM CELLS OF PERIPHERAL BLOOD
DE69831957T3 (en) * 1997-07-14 2009-07-23 Osiris Therapeutics, Inc. HEART MUSCLES GENERATION USING MESENCHYMAL STEM CELLS
AU9127098A (en) * 1997-09-04 1999-03-22 Osiris Therapeutics, Inc. Ligands that modulate differentiation of mesenchymal stem cells
US6368636B1 (en) * 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
EP1082410B1 (en) * 1998-05-29 2007-08-01 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
DE69937888T2 (en) 1998-07-31 2009-01-02 Genzyme Corp., Cambridge Process for the preparation of mesenchymal stem cells
KR100870508B1 (en) * 1999-03-10 2008-11-25 유니버시티 오브 피츠버그 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Adipose-derived stem cells and lattices
US20050158289A1 (en) * 1999-07-07 2005-07-21 Simmons Paul J. Mesenchymal precursor cell and use thereof in the repair of bone defects and fractures in mammals
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US8062675B2 (en) * 1999-07-07 2011-11-22 Angioblast Systems, Inc. Mesenchymal precursor cell
US7670628B2 (en) * 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
AUPQ147799A0 (en) * 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
WO2001007679A1 (en) 1999-07-26 2001-02-01 Chemetall Plc Metal surface treatment
DK1226233T3 (en) 1999-08-05 2011-10-03 Abt Holding Co Multipotent adult stem cells and methods for isolation thereof
US6645727B2 (en) * 2000-05-26 2003-11-11 Stemcell Technologies Inc. Antibody compositions for preparing enriched mesenchymal progenitor preparations
US7052907B2 (en) 2000-07-21 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Adult human dental pulp stem cells in vitro and in vivo
JP2004529621A (en) * 2001-02-14 2004-09-30 ティー ファークト，レオ Pluripotent adult stem cells, their origin, methods of obtaining and maintaining them, methods of differentiating them, methods of their use, and cells derived therefrom
FR2827868A1 (en) * 2001-07-30 2003-01-31 Bp Chem Int Ltd Continuous production of styrene polymers, e.g. high-impact polystyrene, involves bulk polymerisation followed by two-stage devolatilisation of the melt in a special system to remove unreacted monomer and oligomers
AUPR703601A0 (en) 2001-08-15 2001-09-06 Peter Maccallum Cancer Institute, The Identification and isolation of somatic stem cells and uses thereof
JP2003052365A (en) * 2001-08-20 2003-02-25 Japan Science & Technology Corp Separation of mesenchymal stem cell from mammalian animal and method for using the same
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
JP4061487B2 (en) * 2002-11-21 2008-03-19 始 大串 Transplant material for angiogenesis and method for producing the same
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
ATE511753T1 (en) * 2003-04-19 2011-06-15 Us Gov Health & Human Serv POSTNATAL STEM CELLS AND THEIR USES
EP1807510A4 (en) 2004-09-24 2008-01-23 Angioblast Systems Inc Multipotential expanded mesenchymal precursor cell progeny (memp) and uses thereof
KR20130100225A (en) 2004-09-24 2013-09-09 안지오블라스트 시스템스 인코퍼레이티드 Method of enhancing proliferation and/or survival of mesenchymal precursor cells (mpc)
GB0812683D0 (en) * 2008-07-11 2008-08-20 Chalabi Rifat A Multi-heat zone gasifier
US7942266B2 (en) * 2009-04-01 2011-05-17 Lincoln Global, Inc. Electrode packaging to reduce handling damage

Also Published As

Publication number Publication date
JP6257559B2 (en) 2018-01-10
AU2004223798B2 (en) 2006-06-15
CA2816489C (en) 2022-08-23
EP1613335B1 (en) 2014-02-12
JP2015156874A (en) 2015-09-03
CN1809632B (en) 2013-06-05
US20060193840A1 (en) 2006-08-31
AU2009227881A1 (en) 2009-11-12
US10421946B2 (en) 2019-09-24
US20070065938A1 (en) 2007-03-22
JP2006521096A (en) 2006-09-21
US20150368614A1 (en) 2015-12-24
AU2009227897A1 (en) 2009-11-12
EP2380969A3 (en) 2011-11-09
SI1613335T1 (en) 2014-08-29
CN103224907A (en) 2013-07-31
JP2013208130A (en) 2013-10-10
CA2816489A1 (en) 2004-10-07
CN103202857A (en) 2013-07-17
JP2017014285A (en) 2017-01-19
AU2006203628A1 (en) 2006-09-07
FR20C1036I2 (en) 2022-11-18
AU2003901668A0 (en) 2003-05-01
NL301059I1 (en) 2020-08-12
JP2017148076A (en) 2017-08-31
JP2015110659A (en) 2015-06-18
CA2520273A1 (en) 2004-10-07
JP2013256515A (en) 2013-12-26
CN1822846A (en) 2006-08-23
AU2004223798A1 (en) 2004-10-07
JP6043469B2 (en) 2016-12-14
AU2006203627A1 (en) 2006-09-07
CA2520390A1 (en) 2004-10-07
AU2009227897B2 (en) 2011-09-15
EP2380971A2 (en) 2011-10-26
ES2784378T3 (en) 2020-09-24
PT1613335E (en) 2014-05-19
EP2380969A2 (en) 2011-10-26
PL1613335T3 (en) 2014-09-30
US20160317581A1 (en) 2016-11-03
JP5721302B2 (en) 2015-05-20
EP2380971A3 (en) 2012-01-25
US20170204373A9 (en) 2017-07-20
CA2520273C (en) 2015-06-02
US7947266B2 (en) 2011-05-24
JP2006521121A (en) 2006-09-21
EP1613741A4 (en) 2007-07-04
WO2004085630A1 (en) 2004-10-07
US9169466B2 (en) 2015-10-27
AU2009227881B2 (en) 2011-08-25
NL301059I2 (en) 2021-09-16
JP6096082B2 (en) 2017-03-15
CN1822846B (en) 2013-03-20
WO2004084921A1 (en) 2004-10-07
ES2689483T3 (en) 2018-11-14
AU2004224830B2 (en) 2006-06-29
AU2004224830A1 (en) 2004-10-07
JP6188435B2 (en) 2017-08-30
DK1613335T3 (en) 2014-05-19
EP1613335A1 (en) 2006-01-11
US20060286077A1 (en) 2006-12-21
EP1613741A1 (en) 2006-01-11
CA2872395A1 (en) 2004-10-07
CN103224907B (en) 2015-05-06
EP2380969B1 (en) 2018-07-04
CA2520390C (en) 2015-03-24
CN1809632A (en) 2006-07-26
EP2380971B1 (en) 2020-02-12
US20120082649A1 (en) 2012-04-05
JP2011072315A (en) 2011-04-14
EP1613335A4 (en) 2007-07-04
ES2465226T3 (en) 2014-06-05
JP2019006814A (en) 2019-01-17
US9175267B2 (en) 2015-11-03
JP6096232B2 (en) 2017-03-15

Similar Documents

Publication Publication Date Title
FR20C1036I2 (en) PERIVASCULAR MESENCHYMAL PRECURSOR CELLS
DE60336590D1 (en) FUEL CELL
DE602004024016D1 (en) Electroacoustic conversion
ATE511364T1 (en) TOOTHBRUSH
DE602005003581D1 (en) ELECTROLYSIS CELL
DE602005000791D1 (en) interconnector
DE502005004462D1 (en) power float
DE602005025931D1 (en) FUEL CELL
IS2736B (en) Makrólíðsamrunaefnasambönd with @ @ @ anti-inflammatory activity
DE602005023645D1 (en) fuel cell
DE602004008220D1 (en) FUEL CELL
DE602005026944D1 (en) FUEL CELL
DE602005022581D1 (en) FUEL CELL
DE602004023588D1 (en) FUEL CELL
DK1665439T3 (en) solid oxide fuel cell
DE602005004061D1 (en) fuel cell unit
DE602004030501D1 (en) fuel cell
DE602004028858D1 (en) fuel cell
DE502004008433D1 (en) CELL
EP1743936A4 (en) Mesenchymal stem cell precursor
DE602004012181D1 (en) Thermo-electrochemical conversion arrangement
DE602005010396D1 (en) FUEL CELL
DE602005017686D1 (en) fuel cell
DE602004014451D1 (en) fuel cell
FI20051310A (en) brush structure